<DOC>
	<DOCNO>NCT00237445</DOCNO>
	<brief_summary>A multinational , multicenter , randomize , double-blind , study area high pneumococcal resistance compare clinical efficacy health outcome outpatients mild moderate Community-Acquired Pneumonia ( CAP ) treat either telithromycin daily 7 day , azithromycin daily 5 day</brief_summary>
	<brief_title>Study Comparing Clinical Efficacy Health Outcomes Outpatients With Mild Moderate Community-Acquired Pneumonia ( CAP ) Treated With Either Telithromycin Once Daily 7 Days , Azithromycin Once Daily 5 Days</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Male female outpatient age 20 great . Subjects positive Binax NOW S. pneumoniae Urinary Antigen Test and/or positive gram stain diplococcus . Subjects ≤ 7 day sign symptoms CAP . Subjects chest xray finding support diagnosis acute pneumonia presence new infiltrate . For subject history chronic obstructive pulmonary disease ( COPD ) , comparison previous chest xray report require confirm find new infiltrates . Subjects diagnosis acute mild moderate CAP base least one following : fever ( oral &gt; 37.5°C/99.5°F axillary &gt; 37.4°C/99.4°F rectal &gt; 38.5°C/101.5°F ) elevate total peripheral white blood cell count &gt; 10,000/mm3 &gt; 15 % immature neutrophil ( band ) , regardless total peripheral white count new sudden onset ( equal less 48 hour ) least two follow sign symptom : cough dyspnea tachypnea ( particularly progressive nature ) pleuritic chest pain purulent sputum production change sputum character auscultatory finding ( rale and/or evidence pulmonary consolidation ) Subjects present follow include study . Subjects CAP require hospitalization . Subjects sign symptom severe CAP lasting great 7 day . Subjects require parenteral antibiotic treatment . Subjects discharge hospital within 10 day study entry . Subjects visible/gross aspiration pneumonia . Subjects concomitant pulmonary disease , condition complication could confound interpretation evaluation drug efficacy safety , include : severe bronchiectasis , cystic fibrosis suspect active pulmonary tuberculosis suspect acute pulmonary embolism emphysema , lung abscess , extra pulmonary extension ( e.g. , meningitis , septic arthritis , endocarditis ) know bronchial obstruction history postobstructive pneumonia . Subjects neoplastic lung disease ( lung cancer ) another malignancy metastatic lung , and/or require chemotherapeutic intervention neoplasm . Subjects infection require administration systemic antimicrobial agent . Subjects progressively fatal disease ; life expectancy ≤3 month . Subjects myasthenia gravis . Subjects concomitant condition , include severe and/or uncontrolled cardiovascular , neurologic , endocrine , severe and/or uncontrolled major systemic disease make implementation protocol interpretation study result difficult . Immunocompromised subject , : know HIV subject CD4+ Tlymphocyte count date less 3 month &lt; 200/mm3 /or HIV subject treat isoniazide clarithromycin prophylaxis neutropenia ( &lt; 1500 neutrophils/mm3 ) attributable acute infectious disease metastatic hematological malignancy splenectomy know hyposplenia asplenia chronic corticosteroid therapy . Subjects history congenital family history long QT syndrome ( exclude previous ECG ) subject know acquire QT interval prolongation Known severe impair renal function show creatinine clearance &lt; 30 ml/min either measure estimate Cockroft formula . Subjects receive 24 hour effective treatment antibiotic , within 7 day prior enrollment study . Subjects know suspected hypersensitivity , know suspect serious adverse reaction telithromycin macrolide antibiotic . Subjects require onstudy treatment medication know potential drug interaction , include ergot alkaloid derivative , terfenadine , astemizole , cisapride , pimozide , simvastatin , atorvastatin lovastatin ( see Section 6.2 ) . Subjects received investigational drug within 1 month prior study entry treatment plan study period . Subjects pregnant breastfeeding . Subjects recent drug alcohol abuse.Subjects mental condition render subject unable understand nature , scope , possible consequence study . Subject investigator subinvestigator , research assistance , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . Subjects already enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>